A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Injection of LY-N001 Injection for the Treatment of Moderate to Advanced Parkinson's Disease With GBA1 Mutations

NCT07685444 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease (PD)

Interventions

GENETIC: LY-N001 Injection

Sponsor

Lingyi Biotech Co., Ltd.